RecruitingPhase 1NCT07244835

A Study of DEG6498 in Participants With Solid Tumors

A First in Human Phase 1 Open-Label, Multicenter, Dose Escalation and Expansion Study of DEG6498 in Patients With Solid Tumors

Sponsor

Degron Therapeutics Co.

Enrollment

100 participants

Start Date

Nov 13, 2025

Study Type

INTERVENTIONAL

Conditions

Malignant Neoplasms

Summary

The goal of this first in human, Phase 1, multi-center, open-label, and 2-part study is to learn whether DEG6498 is safe and tolerable in participants with advanced solid tumors. It will also learn about DEG6498 pharmacokinetics (PK) profile and potential antitumor activity. The main questions it aims to answer are: * what is an appropriate dose to be given to participants? * are the side effects of treatment manageable? Participants who are treated in this study will receive DEG6498 orally once a day and be closely monitored by the treating physicians.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is an early-phase study testing a new investigational drug called DEG6498 in people with solid tumors (cancers in organs or tissues) that have not responded to standard treatments. The main goal is to find the safest dose and to understand how the body processes the drug. **You may be eligible if...** - You are 18 or older with a confirmed solid tumor cancer - Your cancer has stopped responding to standard treatments or no standard treatment is available - You are in adequate general health (able to perform daily activities) - You have not received cancer treatments (chemotherapy, radiation, etc.) within a specified washout period **You may NOT be eligible if...** - You have active cancer in the brain or spinal cord - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding - You have serious active infections or autoimmune conditions Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.